<?xml version="1.0" encoding="UTF-8"?>
<p>Telemedicine can be considered to support patients remotely to reduce in‐person hospital visits during an infectious pandemic 
 <xref rid="onco13306-bib-0042" ref-type="ref">42</xref>. This may include providing a hospital hotline and expanded telehealth capabilities 
 <xref rid="onco13306-bib-0021" ref-type="ref">21</xref>. Telemedicine has been demonstrated to improve access to care and decrease health care costs 
 <xref rid="onco13306-bib-0043" ref-type="ref">43</xref>. Examples of successful telemedicine in oncology include remote chemotherapy supervision, symptom management, survivorship care, palliative care, and clinical trials 
 <xref rid="onco13306-bib-0043" ref-type="ref">43</xref>. Patients who are not currently receiving active therapy may be especially well‐suited for telemedicine follow‐up. Major limitations to telemedicine include the jurisdictional boundaries of the physicians’ practice, the need for training on telemedicine tools that may be limited in a pandemic setting, limitation of physical exam, and telemedicine reimbursement‐related issues 
 <xref rid="onco13306-bib-0043" ref-type="ref">43</xref>.
</p>
